TearScience: Strong Efficacy of LipiFlow Demonstrated Across 31 Peer-Reviewed Reports

Source: TearScience

TearScience announced the results of a major review demonstrating that a single LipiFlow procedure can significantly improve meibomian gland function and relieve symptoms associated with meibomian gland disease (MGD) with efficacy reported for 12 months and longer, according to a company news release. The review by researchers from Korb Associates in Boston, Massachusetts, and the Duke Eye Center, Durham, North Carolina, noted that “a single vectored thermal pulsation treatment allows for reducing dry eye symptoms, improving meibomian gland function and other correlates of the ocular surface health.” To date, more than 79,000 LipiFlow procedures have been performed.

“This review validates the important and fundamental role of LipiFlow in the management of MGD, a prevalent and under-reported disease, and primary contributor to the discomfort and fluctuating vision that accompanies dry eye. Notably, it is one of the leading motivations for many patients seeking an eye care provider,” Alan Carlson, MD, Vice Chair, Development at Duke Eye Center, Durham North Carolina, said in the news release.
Blackie and colleagues looked at data from 23 meeting presentations and 8 peer-reviewed published studies on effects of the vectored thermal pulsation procedure on MGD. According to the report of sponsored and independent studies, 30 of the 31 studies showed a mean improvement in symptom score following a single treatment. All of the studies demonstrated that the LipiFlow treatment was effective in improving meibomian gland function, on average.
Two long-term controlled studies demonstrated mean reduction of dry eye symptoms and mean improvement in gland function for 6 and 12 months, respectively, for patients who received a single LipiFlow procedure. “In both cases, the single 12-min vectored thermal pulsation procedure performed better than the twice-daily ‘standard-of-care’ approach,” the study authors wrote. Blackie and colleagues cautioned that while results of the one uncontrolled long-term study “remain somewhat speculative,” that case series showed lasting mean improvement in meibomian gland function for up to 4 years following treatment.


Related Content